XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

This study tests a combination treatment after surgery for pancreatic cancer. Patients who have had their tumor removed will receive a drug called XH001 alongside an immunotherapy drug and chemotherapy to help prevent the cancer from coming back. **You may be eligible if...** - You are 18–75 years old with a confirmed diagnosis of pancreatic cancer (adenocarcinoma) - You have had a complete or near-complete surgical removal of your tumor (R0 or R1 resection) - You have not received any chemotherapy or other cancer treatment before surgery (no neoadjuvant therapy) - Your cancer marker (CA19-9) was below 100 U/mL before starting treatment - You are in good general health (ECOG score 0 or 1) with an expected survival of more than 12 months **You may NOT be eligible if...** - Your cancer has come back or spread after surgery - You have fluid build-up in the abdomen caused by cancer - You have inflammatory bowel disease, bowel blockage, or severe diarrhea after surgery - You have had a recent stroke, heart attack, or severe heart failure - You have a history of autoimmune disease Talk to your doctor to see if this trial is right for you.